Ontario’s Measles Outbreak Requires Much More Visible & Effective Public Health Response
TORONTO, April 11, 2025 (GLOBE NEWSWIRE) -- The Ontario Health Coalition is raising concerns about the sharp increase in people...
Vaccine
Qnovia, Inc. Announces Leadership Transition and Strategic Appointments to Support UK Commercialization Strategy
Mario Danek Appointed President and CEO; James Watson Joins as COO, Francesca Lanuza Appointed Director of Regulatory Affairs, and Dr....
Evaxion to present at World Vaccine Congress
Congress will take place April 21-24, 2025, in Washington, D.C.COPENHAGEN, Denmark, April 10, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX)...
Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at ESCMID Global 2025
Highlights will include data from non-clinical and real-world patient useBOSTON, April 10, 2025 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a...
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting
NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced the presentation of data yesterday highlighting...
NOVA’s Concierge Medicine Boom is a Game Changer for Patients
CHICAGO, April 10, 2025 /PRNewswire/ -- Home to some of the nation's most renowned hospitals and healthcare research centers, Northern...
Tonix Pharmaceuticals and Makana Therapeutics Announce Collaboration Combining Tonix’s Anti-CD40L Monoclonal Antibody (TNX-1500) with Makana’s Genetically Engineered Organs in Preclinical and Clinical Xenotransplantation Studies
Agreement includes the use of Tonix’s TNX-1500, as part of an immunomodulatory regimen to reduce rejection of Makana’s genetically engineered...
ENA Respiratory Partners with University of Maryland and Leading Respiratory Disease Expert to Conduct Phase 2 Study of INNA-051 Antiviral Host Defence Enhancer
Phase 2 to evaluate safety, tolerability and efficacy of INNA-051 in the prevention of illness due to viral respiratory infectionsStudy...
ValoTx Appoints Marcella Origgi from Johnson & Johnson Innovation as CEO
HELSINKI and NAPLES, Italy, April 09, 2025 (GLOBE NEWSWIRE) -- Valo Therapeutics Oy (ValoTx), an immunotherapy company developing novel, adaptable...
Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2
Saint Herblain (France) and Schlieren (Zurich), April 9, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine...
Serina Therapeutics Secures $5 Million in Funding to Support Advancement of SER-252 into Clinical Development in Advanced Parkinson’s Disease
HUNTSVILLE, Ala., April 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing...
Rapid Dose Therapeutics Provides Update on the Clinical Trial Development and the Commitment to NFL Funded Cannabinoid Research
Burlington, Ontario--(Newsfile Corp. - April 8, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company"), a Canadian biotech...
Defence Launches Accum Combined with Actinium-225 to Increase Efficacy and Safety of Radio-Immunoconjugate Cancer Therapies
Montreal, Quebec--(Newsfile Corp. - April 8, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"),...
Teva and Samsung Bioepis Announce Biosimilar EPYSQLI® (eculizumab-aagh) Injection Now Available in the United States
EPYSQLI® (eculizumab-aagh) is now available to patients living with difficult-to-treat rare diseases like paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome...
BREAKTHROUGH PRIZE ANNOUNCES 2025 LAUREATES IN LIFE SCIENCES, FUNDAMENTAL PHYSICS, AND MATHEMATICS
"Oscars® of Science" Awards Six $3 Million Prizes GLP-1 Diabetes and Obesity Discovery | Multiple Sclerosis Causes and Treatments | DNA...
Rapid Dose Therapeutics to Showcase Xylistrip, a Dental Product, at Key Tradeshows Across Canada
Burlington, Ontario--(Newsfile Corp. - April 3, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company"), a Canadian...
Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines
Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines Designation granted for warm...
Former Pfizer R&D Chief Mikael Dolsten Joins Formation Bio to Chair Drug Picking Committee and Co-Chair its Investment Advisory Committee
NEW YORK, April 2, 2025 /PRNewswire/ -- Formation Bio, an AI-driven pharmaceutical company revolutionizing drug development, today announced that Mikael Dolsten,...
Appili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on April 4, 2025
Event exploring the escalating threat of emerging infectious diseases Discussion covering going-private transaction with Aditxt, strategic growth partner HALIFAX, Nova...
Rapid Dose Therapeutics Corp. Announces Payment in Shares for Quarterly Interest on Secured Debt and Update on Shares for Debt Settlement with Creditors
Burlington, Ontario--(Newsfile Corp. - April 1, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") announced today...